Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Raptor Pharmaceuticals Corp. (RPTP)

-NasdaqGM
8.23 Down 0.27(3.18%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Raptor Pharmaceuticals Corp.
5 Hamilton Landing
Suite 160
Novato, CA 94949
United States - Map
Phone: 415-408-6200
Fax: 415-382-8002
Website: http://www.raptorpharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:70

Business Summary 

Raptor Pharmaceuticals Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. It markets PROCYSBI, a delayed-release capsule used for the management of nephropathic cystinosis in adults and children six years and older in the United States. The company also commercializes PROCYSBI in the 28 member states of the European Commission plus Norway, Liechtenstein, and Iceland. Its clinical development products include RP103 used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidate is Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical programs comprise cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Raptor Pharmaceuticals Corp.

Corporate Governance 
Raptor Pharmaceuticals Corp.’s ISS Governance QuickScore as of Apr 1, 2014 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 9; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Christopher M. Starr Ph.D., 62
Co-Founder, Chief Exec. Officer, Director, Chief Exec. Officer of Raptor Pharmaceutical Inc and Director of Raptor Pharmaceutical Inc
670.00K1.05M
Ms. Georgia Erbez , 47
Chief Financial Officer, Principal Accounting Officer, Treasurer and Sec.
505.00K0.00
Ms. Julie Anne Smith , 43
Chief Operating Officer and Exec. VP of Strategy
592.00K0.00
Mr. Thomas E. Daley , 51
Chief Bus. Officer
422.00K120.00K
Dr. Todd C. Zankel Ph.D., 50
Co-Founder and Chief Scientific Officer
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders